



Living Cell Technologies Limited

CAN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

LCT collaborates to develop novel neurological treatments

29 September 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited has formed a collaboration with the Centre for Brain Research (CBR). The research collaboration will identify additional neurodegenerative disease targets for clinical studies of LCT's lead product NTCELL®.

Directed by Professor Richard Faull, ONZM MBChB PhD DSc FRSNZ, University of Auckland Distinguished Professor, the CBR has a specialised interest in neurodegenerative diseases such as Parkinson's, Huntington's, motor neurone and Alzheimer's diseases.

LCT has the expertise to identify and commercialise treatments and products from CBR research. Its therapeutic treatment NTCELL is currently in a Phase I/IIa clinical study targeting Parkinson's patients who have failed current symptomatic therapy.

Professor Richard Faull said, "The results of LCT's research studies are impressive and provide strong evidence that NTCELL has the potential to provide significant improvement in patients with Parkinson's disease. We believe this collaboration can help realise the potential of cell therapy for neurodegenerative diseases."

Dr Ken Taylor, LCT chief executive said, "The collaboration is in line with our focus to develop and market NTCELL therapy for Parkinson's patients failing current therapy while also investigating the potential of our patented cell therapy for other neurodegenerative disorders."

– Ends –

For further information: www.lctglobal.com

| | |
|--|--|
| At the company: Ken Taylor Chief Executive Tel: +64 9 276 2690 Mobile: +64 21 796 000 ktaylor@lctglobal.com | Media enquires: Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 rachaelj@botica.co.nz |
|--|--|

About Living Cell Technologies

Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT's lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing factors to promote new central nervous system growth and repair disease induced nerve degeneration.

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson's disease. It has the potential to be used in a number of other central nervous system indications such as Huntington's, Alzheimer's and motor neurone diseases.

LCT's proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

LCT disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential", "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

About the Centre for Brain Research

The Centre for Brain Research at the University of Auckland is a unique partnership between scientists, doctors and the community. The CBR brings together over 59 different research teams from across The University of Auckland. Bridging the Faculty of Medical and Health Sciences, Faculty of Science, and Faculty of Arts the centre has over 350 researchers all working towards the common goal of understanding the brain and finding and developing new treatments for neurological disorders. <https://www.fmhs.auckland.ac.nz/en/faculty/cbr.html>

For more information contact;

Sara Reid, Communications Coordinator

Centre for Brain Research
The University of Auckland
Email: sara.reid@auckland.ac.nz
Phone + 64 9 923 1913